Table 2 Comparison of clinicopathological features according to genetic status
Clinicopathological characteristics | Mutant status | P-value | ||
|---|---|---|---|---|
EGFR (N = 404) | KRAS (N = 98) | Wild type (N = 375) | ||
Age, years | ||||
Median (range, interquartile range) | 68 (41–91, 63–75) | 70 (49–89, 63–75) | 68 (31–89, 61.5–74) | N.S. |
Sex, N (%) | ||||
Male | 173 (42.8) | 55 (56.1) | 211 (56.3) | Figure 1 |
Female | 231 (57.2) | 43 (43.9) | 164 (43.7) | |
Smoking status, N (%) | ||||
Never | 239 (59.2) | 35 (35.7) | 178 (47.5) | Figure 1 |
Current or ex- | 165 (40.8) | 63 (64.3) | 197 (52.5) | |
Surgical procedure, N (%) | ||||
Pneumonectomy | 0 (0.0) | 0 (0.0) | 1 (0.3) | |
Lobectomy | 204 (50.5) | 44 (44.9) | 183 (48.8) | N.S. |
Segmentectomy | 135 (33.4) | 31 (31.6) | 125 (33.3) | N.S. |
Wedge resection | 65 (16.1) | 23 (23.5) | 66 (17.6) | N.S. |
Pathological invasive size, mm | ||||
Median (range, interquartile range) | 10 (0–50, 4–18.25) | 11.25 (0–45, 3–16.74) | 10.0 (0–65, 3–18) | N.S. |
Histological predominance, N (%) | ||||
in situ | 65 (16.1) | 20 (20.4) | 71 (18.9) | N.S. |
Minimally invasive | 54 (13.4) | 10 (10.2) | 39 (10.4) | N.S. |
Lepidic | 71 (17.6) | 12 (12.2) | 64 (17.1) | N.S. |
Papillary | 196 (48.5) | 43 (43.9) | 158 (42.1) | N.S. |
Acinar | 6 (1.5) | 3 (3.1) | 15 (4.0) | N.S. |
Micropapillary | 9 (2.2) | 3 (3.1) | 5 (1.3) | N.S. |
Solid | 3 (0.7) | 7 (7.1) | 23 (6.1) | Figure 1 |
Accompanied > 5% pathological component, N (%) | ||||
Lepidic | 359 (88.9) | 74 (75.5) | 289 (77.1) | Figure 1 |
Micropapillary | 68 (16.8) | 17 (17.3) | 61 (16.3) | N.S. |
Solid | 40 (9.9) | 24 (24.5) | 60 (16.0) | Figure 1 |
IASLC histological grade | ||||
G1 | 69 (17.1) | 12 (12.2) | 64 (17.1) | N.S. |
G2 | 183 (45.3) | 32 (32.7) | 145 (38.7) | 0.0233ek |
G3 | 33 (8.2) | 24 (24.5) | 56 (14.9) | Figure 1 |
Pleural invasion, N (%) | ||||
Pl0 | 369 (91.3) | 84 (85.7) | 328 (87.5) | N.S. |
Pl1 | 24 (5.9) | 12 (12.2) | 26 (6.9) | 0.0300ek |
Pl2 | 8 (2.0) | 2 (2.0) | 10 (2.7) | N.S. |
Pl3 | 3 (0.7) | 0 (0.0) | 11 (2.9) | 0.0215ew |
Lymphatic invasion, N (%) | ||||
Negative | 373 (92.3) | 11 (11.2) | 334 (89.1) | Figure 1 |
Positive | 31 (7.7) | 87 (88.8) | 41 (10.9) | |
Vascular invasion, N (%) | ||||
Negative | 347 (85.9) | 12 (12.2) | 310 (82.7) | Figure 1 |
Positive | 57 (14.1) | 86 (87.8) | 65 (17.3) | |
Intrapulmonary metastasis, N (%) | ||||
Negative | 400 (99.0) | 94 (95.9) | 365 (97.3) | 0.0283ek |
PM1 | 4 (1.0) | 4 (4.1) | 10 (2.7) | |
Pathological T status, N (%) | ||||
Tis | 65 (16.1) | 20 (20.4) | 70 (18.7) | N.S. |
T1a (mi) | 54 (13.4) | 10 (10.2) | 39 (10.4) | N.S. |
T1a | 89 (22.0) | 14 (14.3) | 74 (19.7) | N.S. |
T1b | 101 (25.0) | 26 (26.5) | 99 (26.4) | N.S. |
T1c | 41 (10.1) | 7 (7.1) | 27 (7.2) | N.S. |
T2a | 43 (10.6) | 15 (15.3) | 40 (10.7) | N.S. |
T2b | 4 (1.0) | 2 (2.0) | 6 (1.6) | N.S. |
T3 | 7 (1.7) | 4 (4.1) | 20 (5.3) | 0.0061ew |
Adjuvant chemotherapy, N (%) | ||||
Done | 94 (23.3) | 20 (20.4) | 83 (22.1) | N.S. |
None | 310 (76.7) | 78 (79.6) | 292 (77.9) | |
Recurrence, N (%) | ||||
Positive | 35 (8.7) | 13 (13.3) | 22 (5.9) | 0.0127kw |
Negative | 369 (91.3) | 85 (86.7) | 353 (94.1) | |